Login / Signup

VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance.

Cathy Pichol-ThievendOceane AnezoAafrin M PettiwalaGuillaume BourmeauRemi MontagneAnne-Marie LynePierre-Olivier GuichetPauline DeshorsAlberto BallestínBenjamin BlanchardJuliette ReveillesVidhya Madapusi RaviKevin JosephDieter Henrik HeilandBoris JulienSophie LeboucherLaetitia BessePatricia LegoixFlorent DingliStephane LivaDamarys LoewElisa GianiValentino RibeccoCharita FurumayaLaura Marcos-KovandzicKonstantin MasliantsevThomas DaubonLin WangAaron A DiazOliver SchnellJürgen BeckNicolas ServantLucie Karayan-TaponFlorence M G CavalliGiorgio Seano
Published in: Nature communications (2024)
Glioblastoma (GBM) is a highly lethal type of cancer. GBM recurrence following chemoradiation is typically attributed to the regrowth of invasive and resistant cells. Therefore, there is a pressing need to gain a deeper understanding of the mechanisms underlying GBM resistance to chemoradiation and its ability to infiltrate. Using a combination of transcriptomic, proteomic, and phosphoproteomic analyses, longitudinal imaging, organotypic cultures, functional assays, animal studies, and clinical data analyses, we demonstrate that chemoradiation and brain vasculature induce cell transition to a functional state named VC-Resist (vessel co-opting and resistant cell state). This cell state is midway along the transcriptomic axis between proneural and mesenchymal GBM cells and is closer to the AC/MES1-like state. VC-Resist GBM cells are highly vessel co-opting, allowing significant infiltration into the surrounding brain tissue and homing to the perivascular niche, which in turn induces even more VC-Resist transition. The molecular and functional characteristics of this FGFR1-YAP1-dependent GBM cell state, including resistance to DNA damage, enrichment in the G2M phase, and induction of senescence/stemness pathways, contribute to its enhanced resistance to chemoradiation. These findings demonstrate how vessel co-option, perivascular niche, and GBM cell plasticity jointly drive resistance to therapy during GBM recurrence.
Keyphrases